Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865850 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A Phase 3 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT02865850 is a Phase 3 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 369 participants.
The verdict
NCT02865850, a Phase 3 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
Interventions
- DRUG Vadadustat
- DRUG Darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865850
The ClinicalTrials.gov registry entry for NCT02865850 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vadadustat is the first listed.
NCT02865850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02865850 about?
NCT02865850 is a clinical study titled "Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)". A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
What is the current status of trial NCT02865850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2016-07. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT02865850?
The interventions under investigation include: Vadadustat (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT02865850?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.